Orser Capital Management LLC Boosts Stake in Zoetis Inc. (NYSE:ZTS)

Orser Capital Management LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 1.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,866 shares of the company’s stock after buying an additional 93 shares during the quarter. Zoetis accounts for 1.3% of Orser Capital Management LLC’s portfolio, making the stock its 25th biggest holding. Orser Capital Management LLC’s holdings in Zoetis were worth $1,732,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of ZTS. Belpointe Asset Management LLC boosted its position in Zoetis by 24.8% during the fourth quarter. Belpointe Asset Management LLC now owns 2,071 shares of the company’s stock worth $409,000 after purchasing an additional 412 shares in the last quarter. Exencial Wealth Advisors LLC boosted its position in Zoetis by 8.9% during the fourth quarter. Exencial Wealth Advisors LLC now owns 3,130 shares of the company’s stock worth $618,000 after purchasing an additional 257 shares in the last quarter. Morningstar Investment Services LLC purchased a new stake in Zoetis during the fourth quarter worth $332,000. Prudential PLC boosted its position in Zoetis by 1.1% during the fourth quarter. Prudential PLC now owns 33,260 shares of the company’s stock worth $6,565,000 after purchasing an additional 377 shares in the last quarter. Finally, Waterloo Capital L.P. purchased a new stake in Zoetis during the fourth quarter worth $504,000. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Down 0.5 %

NYSE:ZTS traded down $0.96 on Friday, hitting $190.03. 1,697,760 shares of the stock were exchanged, compared to its average volume of 2,576,563. The stock has a market cap of $86.09 billion, a PE ratio of 36.61, a PEG ratio of 2.95 and a beta of 0.89. The company has a current ratio of 3.45, a quick ratio of 2.09 and a debt-to-equity ratio of 1.32. The stock has a fifty day moving average of $187.30 and a 200-day moving average of $175.47. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm posted $1.41 earnings per share. As a group, equities analysts expect that Zoetis Inc. will post 5.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Stifel Nicolaus upped their price objective on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a research report on Wednesday, September 18th. Piper Sandler upped their price objective on Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research upped their price objective on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Argus upgraded Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $220.38.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.